For instance, a recent randomized phase II study showed that the combination of the anti-CSF1 monoclonal antibody lacnotuzumab (MCS110) with gemcitabine and carboplatin yielded comparable anti-tumor efficacy to gem-carbo alone in a total of 50 patients with advanced triple-negative breast cancer (TNBC) [27]. The gene discussed is CSF1; the disease is neoplasm.